Qiu Li

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 16

Top Topics

Chronic Lymphocytic Leukemia

Metastatic Colorectal Cancer

Radiation Therapy

Top Venues

Cancer medicine

European journal of cancer care

Computational and mathematical methods in medicine

Liver international : official journal of the International Association for the Study of the Liver

This page only lists publications with an associated author ORCID identifier.

Publications

Feng Wen, Peng Huang, Qiuji Wu, Yang Yang, Kexun Zhou, Mengxi Zhang, Qiu Li
Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis. Cancer medicine 13 (16) (2024)
Feng Wen, Peng Huang, Qiuji Wu, Yang Yang, Kexun Zhou, Mengxi Zhang, Qiu Li
Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis. Cancer medicine 13 (16) (2024)
Feng Wen, Peng Huang, Qiuji Wu, Yang Yang, Kexun Zhou, Mengxi Zhang, Qiu Li
Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis. Cancer medicine 13 (16) (2024)
Qiucen Li, Zedong Du, Zhikui Chen, Xiaodi Huang, Qiu Li
Multiview Deep Forest for Overall Survival Prediction in Cancer. Computational and mathematical methods in medicine 2023 (2023)
Qiucen Li, Zedong Du, Zhikui Chen, Xiaodi Huang, Qiu Li
Multiview Deep Forest for Overall Survival Prediction in Cancer. Computational and mathematical methods in medicine 2023 (2023)
Peng-Fei Zhang, Xuan-Qiong Shi, Qiu Li
Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis. Cost effectiveness and resource allocation : C/E 21 (1) (2023)
Weiting Liao, Yu Yang, Huazhen Yang, Yuanyuan Qu, Huan Song, Qiu Li
Circulating gamma-glutamyl transpeptidase and risk of pancreatic cancer: A prospective cohort study in the UK Biobank. Cancer medicine (2022)
Feng Wen, Hanrui Zheng, Pengfei Zhang, Weiting Liao, Kexun Zhou, Qiu Li
Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states. Liver international : official journal of the International Association for the Study of the Liver 41 (5) (2021)
Yu-Wen Zhou, Yi-Xiu Long, Ye Chen, Zhenhua Liu, Dan Pu, Jia-Yan Huang, Feng Bi, Qiu Li, Hong-Feng Gou, Meng Qiu
First-line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component. Cancer medicine 10 (10) (2021)
Peng-Fei Zhang, Ze-Dong Du, Feng Wen, Feng-Yi Zhang, Wei-Han Zhang, Li Luo, Jian-Kun Hu, Qiu Li
Development and validation of a nomogram for predicting overall survival of gastric cancer patients after D2R0 resection. European journal of cancer care 29 (5) (2020)
Peng-Fei Zhang, Dan Xie, Qiu Li
Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma. Future oncology (London, England) 16 (17) (2020)
Mei Zhan, Hanrui Zheng, Yu Yang, Zhiyao He, Ting Xu, Qiu Li
Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial. Cancer management and research 12 (2020)
Peng-Fei Zhang, Dan Xie, Feng Wen, Qiu Li
Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost-effectiveness analysis. Cancer medicine 9 (15) (2020)
Weiting Liao, Jiaxing Huang, David Hutton, Guiqi Zhu, Qiuji Wu, Feng Wen, Liangliang Bai, Qiu Li
Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma. Liver international : official journal of the International Association for the Study of the Liver 39 (12) (2019)
Xiaofeng He, Wenwen Chen, Dan Tang, Feng Wen, Pengfei Zhang, Qiu Li
Factors related to the receipt of adjuvant therapy among patients with gastric cancer in Western China. European journal of cancer care 28 (3) (2019)
Feng Wen, Hanrui Zheng, Pengfei Zhang, Jing Zhou, Hongdou Chen, Kexun Zhou, Qiu Li, Feng Bi
Patient-based cost-effectiveness analysis of FOLFIRI versus FOLFOX7 for advanced gastric adenocarcinoma in China: A 4-year prospective randomised phase II study. European journal of cancer care 29 (1) (2019)